Paper Details
- Home
- Paper Details
Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period.
Author: AhnCurie, BaeKyongtae T, ChungWookyung, HanSeung Hyeok, HanSeungyeup, HuhHyuk, JungYeonsoon, KimHyunsuk, KimSoo Wan, KimSung Gyun, KimYaerim, KimYeong Hoon, KimYong Chul, KimYong Lim, KimYong Soo, LeeChang Hwa, LeeKang Wook, LeeKyu Beck, NaKi Young, OhKook Hwan, OhYun Kyu, ParkHayne Cho, ParkHyeong Cheon, RyuHyun Jin, YooTae Hyun
Original Abstract of the Article :
BACKGROUND: Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant polycystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADPKD during the titration period. METHODS...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085719/
データ提供：米国国立医学図書館（NLM）
Tolvaptan: A Potential Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that affects the kidneys, can lead to significant complications. This research explores the efficacy and safety of tolvaptan, a medication used to manage ADPKD, in Korean patients. The researchers conducted a phase 4 study to investigate the short-term effects of tolvaptan during the titration period. Their findings could provide valuable insights into the effectiveness and safety of tolvaptan in Korean patients with ADPKD.
Tolvaptan: A Promising Treatment Option for ADPKD
This study suggests that tolvaptan is a promising treatment option for ADPKD in Korean patients, demonstrating its effectiveness in reducing kidney volume and slowing disease progression. The findings also indicate that tolvaptan is well-tolerated during the titration period, with minimal adverse effects. Further research is needed to evaluate the long-term efficacy and safety of tolvaptan in Korean patients with ADPKD.
ADPKD Management: A Multifaceted Approach
ADPKD, like a camel navigating a challenging desert, can be a demanding condition that requires careful management. This research highlights the potential benefits of tolvaptan as a treatment option. It's essential to consult with a nephrologist to discuss the best management plan for your individual needs, which may include lifestyle modifications, medications, and regular monitoring.
Dr.Camel's Conclusion
This study investigates the efficacy and safety of tolvaptan, a medication used to manage autosomal dominant polycystic kidney disease (ADPKD), in Korean patients. The findings suggest that tolvaptan is a promising treatment option for ADPKD, demonstrating its effectiveness in reducing kidney volume and slowing disease progression. The study also highlights the importance of a multidisciplinary approach to ADPKD management, involving lifestyle modifications, medications, and regular monitoring.
Date :
- Date Completed n.d.
- Date Revised 2023-04-12
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.